Atorvastatin Before Prostatectomy and Prostate Cancer

• Status: Completed
• Trial end date: 2017-05-01
• Target enrollment: 0
• Participant gender: Male

Summary

This single-center, randomized, double-blind trial assesses the impact of short-term atorvastatin administration on proliferation activity, apoptotic rate and histological inflammation in prostate tissue.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tampere University Hospital
• Collaborators: Fimlab laboratories; Finnish Cultural Foundation; Tampere University; University of Eastern Finland; University of Tampere
• Treatments: Atorvastatin; Atorvastatin Calcium

Criteria

Inclusion Criteria:

• Prostate cancer proven histologically in prostate biopsy

• Radical prostatectomy selected as the first-line treatment

• Willingness to participate and sign informed consent

Exclusion Criteria:

• Previous oncological treatments for any malignancy

• Previous usage of statins, finasteride or dutasteride within a year prior to prostate cancer diagnosis

• Clinically significant liver- or kidney insufficiency (plasma alanine aminotransferase level is twice over the recommended upper limit or serum creatinine level is over 170 µmol/l)

• Previous adverse effects from cholesterol-lowering treatment

• Ongoing use of drugs having interactions with statins (St John's Wort, HIV protease inhibitors, ciclosporin, macrolide antibiotics, fusidic acid, phenytoin, carbamazepine, dronedarone or oral antifungal medication)